Literature DB >> 8578504

Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis.

R M Bertina1, P H Reitsma, F R Rosendaal, J P Vandenbroucke.   

Abstract

The recent discovery of the factor V Leiden mutation as the molecular defect in the large majority of APC-resistant individuals, has drastically changed our view on familial thrombophilia and it has contributed to a better understanding of the interaction of genetic and environmental risk factors. It has offered firm support for the view that venous thrombosis is a multifactorial disease and that the risk of thrombosis will increase as the number of genetic and/or environmental risk factors increases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8578504

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

1.  A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assay.

Authors:  M Ledford; K D Friedman; M J Hessner; C Moehlenkamp; T M Williams; R S Larson
Journal:  J Mol Diagn       Date:  2000-05       Impact factor: 5.568

2.  Endogenous thrombin potential changes during the first cycle of oral contraceptive use.

Authors:  Carolyn L Westhoff; Malcolm C Pike; Serge Cremers; Andrew Eisenberger; Stella Thomassen; Jan Rosing
Journal:  Contraception       Date:  2017-01-11       Impact factor: 3.375

3.  [Postthrombotic leg ulcers in heterozygote factor V Leiden mutation].

Authors:  C Blazek; M Megahed; D Höller Obrigkeit
Journal:  Hautarzt       Date:  2007-11       Impact factor: 0.751

4.  Functional Consequences of Mannose and Asialoglycoprotein Receptor Ablation.

Authors:  Yiling Mi; Marcy Coonce; Dorothy Fiete; Lindsay Steirer; Gabriela Dveksler; R Reid Townsend; Jacques U Baenziger
Journal:  J Biol Chem       Date:  2016-07-12       Impact factor: 5.157

5.  Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis.

Authors:  A E Mahmoud; E Elias; N Beauchamp; J T Wilde
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

6.  Prevalence of factor V Leiden in a Canadian blood donor population.

Authors:  D H Lee; P A Henderson; M A Blajchman
Journal:  CMAJ       Date:  1996-08-01       Impact factor: 8.262

7.  Prevalence of resistence to activated protein C (APC-resistance) in blood donors in Kosovo.

Authors:  Ymer Mekaj; Bukurije Zhubi; Hakif Hoxha; Remzije Belegu; Agon Mekaj; Ermira Miftari; Mazllum Belegu
Journal:  Bosn J Basic Med Sci       Date:  2009-11       Impact factor: 3.363

8.  APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.

Authors:  Sara Sedano-Balbás; Mark Lyons; Brendan Cleary; Margaret Murray; Geraldine Gaffney; Majella Maher
Journal:  BMC Pregnancy Childbirth       Date:  2010-03-10       Impact factor: 3.007

9.  Multiplex assay for genetic testing of thrombophilia: a method for routine clinical care.

Authors:  Mónica López; Pilar Giraldo; Patricia Alvarez; R Cornudella; Miguel Pocoví; Antonio Martínez; Jordi Fontcuberta; José Manuel Soria
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

10.  Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores).

Authors:  Claudia C Branco; Tânia Pereirinha; Rita Cabral; Paula R Pacheco; Luisa Mota-Vieira
Journal:  Thromb J       Date:  2009-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.